Between January 1. 1989. and December 31. 1994. we bave treated-t22 primary beart recipients with FK 506 (group I) and 121 ~ith cyclosporine (group m. Fifty patients in tbe cyclosporine (CyAl group received no lympbolytic induction (C~A alone I and 71 others received Iympholytic induction with either rabbit antitbymocyte globulin or 01\.13 (CyA+U). The mean follow-up was longer in tbe FK 506 group tban in the CyA groups (3.2 :!: 1.3 vs 2.3 :t 1.8 years: p < 0.01). Patient survival did not dilfer on tbe basis of the type of immunosuppression used. At 3 months after transplantation. the freedom from rejection in the FK 506 group was higher than tbat of tbe CyA-alone group (47% vs 22%, p < 0.01) but similar to that of the CyA+U group (47% vs 53%). The linearized rejection rate (episodes/tOO patient-days) of the FK 506 group (0.09 episodes) was lower (p < 0.05) tban tbat of the CyA-alone group (0.26) and the CyA+U group (0.13). The requirement for pulsed steroids to treat rejection was less in common in tbe FK 506 group than in eitber CyA group. Eighteen patients in the CyA group had refractory rejections: all resolved with FK 506 rescue. Two patients in the FK 506 group had refractory rejection that resoh'ed with totallympboid irradiation (n = 11 and methotrexate therapy (n = 1). Patients receiving FK 506 bad a lower risk of hypertension and required a lower dose of steroids. Altbough the mean serum creatinine concentration at 1 year was higher in the FK 506 group. this dilference disappeared after 2 years. No patients required discontinuation of FK 506 because of its side effects. Our intermediate-term results indicate that FK 506 compares favorablv with CyA as a primary immunosuppressant in heart transplantation. (J THORAC CARDIOVASC SURG 1996:111:764-72) T acrolimus (FK 506). a macrolide lactone derived from the fungus Screptomvces csurobaensis. was recently approved by the Food and Drug Administration for use as an immunosuppressive agent in liver transplantation. In vitro FK 506 has been found to be lLl to 100 times more potent than cyclosporine (CyA I in its immunosuppressive prooerties. I.:! We first introduced FK 506 into clinical heart transplantation In October 1989 and have since treated 122 primary heart recipients with this drug. This report summarizes our 5-year experience \\;th the use of FK 506 as a primary immunosuppressant in heart transplantallon. We will compare the clinical outcome of heart recipients treated with FK 506 with that of a concurrent cohort treated with a C~A.-based regimen. 
T acrolimus (FK 506). a macrolide lactone derived from the fungus Screptomvces csurobaensis. was recently approved by the Food and Drug Administration for use as an immunosuppressive agent in liver transplantation. In vitro FK 506 has been found to be lLl to 100 times more potent than cyclosporine (CyA I in its immunosuppressive prooerties. I.:! We first introduced FK 506 into clinical heart transplantation In October 1989 and have since treated 122 primary heart recipients with this drug. This report summarizes our 5-year experience \\;th the use of FK 506 as a primary immunosuppressant in heart transplantallon. We will compare the clinical outcome of heart recipients treated with FK 506 with that of a concurrent cohort treated with a C~A.-based regimen. transplantation. P:.Itients who had st!cond transplants or multiplt! organ transplants or who dit!d within 7 davs atter transplantation because or primary graft failure wert! t:xcluded from the anaivsis.
Between J anuar\, I. i 9~9. and December 31. 1l}94. 2.+3 ht!art transplant reCipients at our center met these criteria. .-\ total of 122 patients received an FK 506-hased immunosuppression protocoi. and 121 were treated With a CvA-hased regimen. From Januarv to September. 1989 all patients received CvA-based immunosuppression. When FK 506 was available tor clinicai trial in heart transpiantatlon at our center in October 1989. all heart transplant recipients were considered as potential candidates for the FK 506 protocol. CyA was used only when informed consent could not be obtained or when there were restrictions trom thirdpartY payers on the use of experimental drugs.
The use of FK 506 was approved by the Institutional Review Board at the Cniversitv of Pittsbureh. and informed consent was obtained from every patient.
The demographic data tor these patients are summarized in Table I transplantation. the dose of prednisone was reduced to 0.3 mg/kg. and steroids were weaned further after 6 months. Azathioprine was administered as in the CyA~LI group. Monitoring for rejection. Surveillance for reJection in· volves weekly endomyocardial biopSIes during the tirst month. monthly for the next 3 months. and every 3 months for the remaining tirst year. Thereafter. biopSIes are performed semiannually. In addition. endomvocardial bi· opsies are performed whenever clinically indIcated. In infants and small children. endomyocardial biopsies are performed less freouently because of the inherent techni· cal difficultv. Biopsv specimens are graded according to the criteria of the International Societv for Heart and Lung Transplantation. ' . Treatment of rejection. Acute reiection (grade 3A or higher) IS treated v.ith boluses of methylpreonIsoione (1 grrt/day for adults and 10 to 20 mg/kg per day for pediatric patlents. tor 3 days I. Grade 1 B to 2 re1eCtlOnS are treated by augmenting the baseline doses of the pnmarv immu· nosuppressant (FK 506 or CyA) or steroids. OKT3 or ATG is reserved for steroid·reslstant rejections.
Monitoring for infection. Pretransplantauon titers ior herpesvirus. hepatltls A. B. and C viruses. and Toxoplasma c;ondii were obtamed on every patient. After transplanta· tion. all patients were lollowed up by an infectiOUs disease specialist. Infections were diagnosed according to previ-(luslv established cnteria." Onlv maior infections. as pre· viously denned." that necessItated hospltalizatlon tor m· travenous drug therapy were included for analvsis.
Statistical analysis. Actuanal survival. ireedom trom ;lcute rejection. and freedom from allogratt coronarY ;lrteriopathy were computed bv means of life table anal· vsis. These analvses were based on both the Intention-to· ireat method (data were analvzed according to the initial treatment ;lsslgnment) and the \:cnsonng \:rosSO\'C, method (crossover.; were \:ensored when treatment changed). ,,' II SUTVI\'al curves were comparell b\' means of the log·rank IMantel·Cox) test. Differences ID group means were comDared hv the [ rest. ~,nu ~Inal\,s!s ,11 variance for repeated measures with adjustment was made for compansonwise error.l~ Differences in proportions were compared by the i" test. A p value less than 0.05 was considered statistically signiticant. For the calculation of incidence rates (epis~des~ per 100 patient-days) of rejection. infection. requirement for steroid bolus. and lympholytic treatments at patients in the CyA group who were converted to FK 506. the rates were calculated from the time of the transplantation to the time of conversion to FK 506. Incidence rates were compared with the use of the two-sample test for incidence-density measure. i3 A sonware package (CSS Slatistica. Release 4.5. Statsoft. Tulsa. Okla. I was used for statistical analvses.
Results
Patient survivals. According to the intention-to· treat analysis. the 1-and 5·year actuarial patient survivals did not differ significantly on the basis of the type of immunosuppressive protocols (CyA :llone. 91 CC and 74%: CyA + LI. 93CC and 69%: FK 506. 90t( and 76%) (Fig. 1) . Because the intentionto·treat analyses have been criticized for not evalu-:lting the true effect of the treatment in studies in which there are significant crossovers (I5SG of pa· tients recelvmg CyA initially were converted to FK 506 r see below 1). we have analvzed the survival data llStn£ ooth the intention-to-treat and the censoring cros~o\'er methods. 10. II In the former method. data :lre anaivzed according to the initial treatment assignment: in the latter, data are censored when there is :l change in treatment (crosso\'erl. There \vas no difference in patient survivals according to the types of immunosuppressive protocols when either method was used.
Causes of death. Twenty-four patients In the FK 506 and 23 in the CyA groups (CyA alone and CyA.,... LI) died during this study (p = not signiricant: Table Il ). The most common causes of death for both groups were rejection and infection. Three patients died of disseminated posttransplant Iymphoproiiferative disease, one in the FK 506 group and two in the CyA group. Four patients in the CyA group died of other malignancies including lung tumor (n = 1), testicular tumor (n = ll. osteosarcoma In = I), and recurrent cardiac rhabdomyosar-
Acute rejection. The actuarial freedom from rejection at 3 months for the CyA-alone group was 22%. significantly lower (p < 0.01) than that of the CyA+LI (53%) and FK506 groups (47CC) (Fig. 2) .
The incidence rate of rejection (episodes per 100 patient-days) in the FK 506 group was significantly lower Ip < 0.05) than that of the CyA-alone or CyA + LI group (Table III) . Steroid boluses used to treat rejection were lower in the FK 506 group than in the CyA-alone (p < 0.01) and the CyA + LI (p < 0.05) groups. There were fewer rejection episodes that necessitated lympholytic treatment in the FK 506 group than m the CyA-alone group IP < 0.01).
Intractable rejection. Thirteen patients in the CyA-alone group and five in the C~A-LI group (four with ATG and one with OKT3) had refractory rejeCtIon that was resistant to conventlonai therapy with at least one course of pulsed steroids and one ~ourse at lvmpholvtic treatment. All 1;) at these patients were successfully treated by conversion to FK SOn. OnlY two pediatric patients in the FK 50n group had retractorv reiection. One reqUIred total lvmphoid irradiation and the other \\as treated 'iuccessfullv with methotrexate.
AlIo2rat't coronary arteriopathy. Allograft coronary artenopathy atter transplantation \\ as l1ctined ~lS an\' lummal irregularity and an\' coronar\' stenosis ,een un the ~oronarv angIogram or ,lnv dilfuse ~oronary artery disease at autopsy. In IS3 patients whose allogrart coronary arteries ~ould be evaluated. the actuarIal freedom from allogran coronarY artenopathy at of years ror the FK 506 ( 103 patients) and eyA (80 patients) groups was s.::re and 73q.. respectively (p = not significant) (Fig. 3) .
Requirement for steroids and azatbioprine. At most recent follow-uo examination llr at the lime of death .. +0 of (")3 adults receiving FK 50b I-+SCc) were trce lit steroIds as ~ompared with 10 initially given CyA. eight required conversion to FK 506 because they could not be weaned from steroids: all of these were eventually free of steroids. AzathIoprine was added to the steroidJFK 506 regimen when serum creatinine concentration was higher than 2 mgJdl or when there were at least two ..:onsecuuve episodes of acute rejectlon that necessitated treatments. At latest follow-up. 43% of patients receiving FK 506 were also receiving azathiopnne.
Infection. A total of 70 episodes 10.05 episodes per 100 oatient-davs ) of major infections occurred in the FK S06 group as compared with 59 episodes 
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Time after transplantation (month) serum creatinine levels at 1 and 2 yearS aner transplantation were higher in the FK 506 group than in the CyA groups (Fig. -I) . However. this difference did not reach statistical significance (by tne analvsis of variance for repeated measures,.
Renal failure necessitating dialysis or kidney transplantation developed in five patients In the FK 5U6 group and in seven in the CyA groups 2 to .5 years after transplantation. In the CyA groups. three patients required dialysis while being treated with CyA alone and tour required dialysis ~Itcr being converted to FK 506. Of these tour patients ..,wltched to FK 5Uo. two had intections I Gnt! mucormycosis and one tuberculosis) that necessitated antibiotics with nephrotoxicity.
Other side effects H'penension. The prevalence of new-onset hypenension in adults in the FK 506 and CyA groups was -lice (39/83) and 84% (80/95). respectively (p < 0.Dl\. In the pediatric group. 10% of the patients treated with FK 506 had hypertension.
Hvperka/emia. Twenty-five adults and one pediatric patient (21 0C) who were receiving FK 506 had persistent hyperkalemia (K->5.0 mEqjL) that necessitated treatment. This was easily controlled with a low dose of ftudroconisone (0.2 mg;day). No patient died of hyperkalemia in this trial.
DiaDeres meiiillls. The prevalence or new-onset
insulin-dependent diabetes mellitus was the same in adults in both the FK 506 (260) and CvA (22o/c) groups. ~ew-onset insulin-dependent diabetes mellitus developed in one of SO pediatric patients recei\'Ing FK 506 (both as a primary agent and after conversion from CyA).
Posrrrallsplalll part. our philosophy to minimize the use of multiple courses of high-dose steroids and lympholytic therapy. In our earlier experience with F1\. 506 as a "rescue" drug for refractory rejection. we observed a very high incidence of posttransplantation lymphoproliferative disease. especially in patients who had received multiple courses of steroids and lympholvtic agents before being converted to FK 506. 2b Excessive use of l~mpholytic treatments is a primary risk factor in the development of posttransplantation lymphoproliferative disease. 27 We therefore strongly believe that early conversion to FK 506 in patients with refractory rejection who are being treated with CyA should reduce this risk. Renal toxicity 1S a major side erl'ect of borh FK 506
and CyA. Studies in liver recipients have shown that nephrotoxicity was comparable between CyA and FK 506 and that the mean serum creatinine levels at vanous time points after transplantation were similar in the two groups. 23 . ~5 In the current study. I year atter transplantation. patients in the FK 506 group had slightly higher mean serum creatinine levels than those in the CyA group IP = not significant). However. this difference disappeared after 2 years. The higher serum creatinine level at I year after transplantation in the FK 506 group probablv reflects our learning curve in the use of this drug. With expenence. we believe that this difference will disappear. Hyperkalemia is a known side effect of FK 5U6 and has been reponed to be independent of renal function. 2s . 2 " This Side etfect was. however. easily treated with a small dose of fludroconisone. Possible mechanisms responsible ior the hyperkalemia include the inability of the distal renal tubules to respond to aldosterone t type IV renal tubular acidosis) and a decrease in the level of plasma renin caused by a depressed cellular activity of the juxtaglomerular system. 30 . 3i
The risks of infection and posuransplantation lymphoproliferative diseases were similar with both FK 506 and CyA. Other advantages of FK 506 over CyA include a lower risk of the development of new-onset hypertension. the lack of gingival hyperplasia. and the lack of coarsening of facial features.
Although the current study is limited by a lack of randomization and involves a different organ. it yields results similar to those of the randomized studies with liver and lung transplantation. In the EUTOoean multicenter trial. which consisted of 545 primary liver recipients. the rate of patient and graft survl\ai was similar between FK 506 and CyA groups: however. patients receiving FK 506 had signiricamlv fewer episodes of acute. refractory acute. and chronic rejection. 25 The multicenter trial in the C nited States consisting of 529 primary liver recipients reponed similar results.: 3 The I-year actuarial survivals were similar between FK 506 and CyA arms. and patients receiving FK 506 had fewer episodes at acute. steroid-resistant. and refractory reJection. Our own randomized trial of FK 506 in lung transplantation. 3 506 is a valuable addition to our armamentarium of immunosuppressive agents. It is at least equal to CyA as a maintenance immunosuppressive agent with regard to survival. and it is superior with regard to morbidities including gingival hyperplasia. hirsutism. and hypertension. I am concerned. however. about the claim that FK 506 offers advantages over CyA-based immunosuppression with regard to the frequency and severity of acute rejection episodes. It must be pointed out. as Dr. Pham has mentioned. that this was not a blinded randomized trial and that enthusiasm for a new agent may often engender subtle therapeutic biases that may compensate the validity of seemingly significant findings. The manuscript describes the strategy of boosting FK 506 doses in the presence of histologically mild rejection episodes in the FK 500 group. In contrast. no comparable strategy of increasmg CyA doses in the control group IS described. This discrepancy raises the question that the lower frequencv of refractory rejection and the higher ouantities of steroids used in the CyA-treated group were due to this difference in dosing strategy rather than mtnnsic differences between the two drugs.
This report also shows that with regard to nephrotoxicity and development of late graft atherosclerosis. FK 506 offers no advantage over CyA. It remains clear that these two problems. particularly the latter. remain the Achilles heel of presently available immunosuppressl\e regImens.
Perhaps the most impressive finding in thIS expenence is the successful treatment of rejection refractory to conventional treatment in 18 CyA-treated patients by sWllching to FK 506. The clinical imponance llt this observation cannot be overestimated and pro\10eS transplant groups with a powerful new tool for an otherwise unmanageable problem.
I have the following questions: Is a randomized maintenance immunosuppressIon trIal between these two agents planned tor nean transplant recipients? If not. is FK 506 the authors· immunosuppressive agent of choice for mamtenance immunosuppressIOn'
Can FK 506 and e,A be used m combmallon ) Could FK 506 be used to initially treat acute relection episodes III CyA-treated patients instead Ol ster01ds or anti-T-cell antibodies?
Last. is the cost of this newly approved drug comparable with the cost of CyA".) Dr. Rose. with regard to the randomized trial. a multicenter trial is going to be conducted in the United States. In Europe. single-center trials wmparing CyA and FK 506 in heart transplantation have heen initiated.
The second question was whether FK 506 was our immunosuppression of choice. The answer is yes. We prefer this medication over Cy.-\ tor all of the advantages that I ha\'e alluded to. Mainh·. it is easier to manage the FK 506-treated patients because there is less rejection and fewer side effects. Compared with CyA. FK 506 has fewer cosmetic side effects. su.:n J~ cushingoid features. hirsutism. and gingival hyperplasia . .-\s you know. after the patients recover from an acute disease. cosmetic issues become a real concern for them, FK 506. therefore. certainly has these additional advantages over CyA.
The third question was whether FK 506 could be used in combination with CyA. In \ltTO. FK 506 and CyA are synergistic in their immunosupt.'TessiH: properties. Ho\\-ever. as far as I know. nobody has tried to combine these medications in a clinical settin~. I suppose. because of the fear of renal toxicity and the complexitv of monitoring these [WO drug levels at the same time. . -The b<t question was whe!~;?~ FI-: 50t) could he used initially to treat the rejection III the CyA-treated patient instead of steroids or anti-T-celi antibodies. The answer is yes. As we have learned over the past 5 years. there was a higher incidence of posttranspiantatlon lymphoproliferalive disease in patients who reQUire FK 506 rescue for rejection that was refractory to other immunosuppressive agents. Because of this problem. \\e are now more aggressive in converting our patients to FK 506. We have aggressive Iv switched our CvA-treated patients to FK 506 when they have relection. and we trv mtentionally not to treat them with multiple doses or steroids and antilympholytic agents.
Regarding the cost of this drug. I was told that this agent was as comparable 10 terms 01 cost to evA. but I do not know the details.
My flnal comments are ttl CIJrIT\ one pomt Dr. Rose made in regard to the strateg\ l't r-oosting FK 506 doses in the presence at histolog.cal1\· mild rejection episodes. \Ve did the same with the CI.-\-treatcd patient if thc evA le\·ei was not considerec te' r>e optimal. Thereforc. the dOSing strategy is similar r-etween the two groups of paticnts.
